冒烟型多发性骨髓瘤风险模型间不吻合的评估。
Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models.
机构信息
Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
John P. Murtha Cancer Center, Hematology-Oncology Department, Walter Reed National Military Medical Center, Bethesda, Maryland.
出版信息
JAMA Oncol. 2021 Jan 1;7(1):132-134. doi: 10.1001/jamaoncol.2020.5585.
Abstract
This cohort study assesses the concordance of 3 models to stratify risk for progression to multiple myeloma in an independent cohort of patients with smoldering multiple myeloma.
摘要
本队列研究评估了 3 种模型在冒烟型多发性骨髓瘤患者独立队列中分层多发性骨髓瘤进展风险的一致性。
相似文献
1
Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models.
JAMA Oncol. 2021 Jan 1;7(1):132-134. doi: 10.1001/jamaoncol.2020.5585.
2
The screening imperative for multiple myeloma.
Nature. 2020 Nov;587(7835):S63. doi: 10.1038/d41586-020-03227-y.
3
Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
J Natl Compr Canc Netw. 2020 Dec 1;18(12):1720-1729. doi: 10.6004/jnccn.2020.7660.
4
Population-based screening cohort study reveals no association between monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), multiple myeloma (MM), and alopecia.
Arch Dermatol Res. 2024 Sep 14;316(9):627. doi: 10.1007/s00403-024-03372-8.
5
Smoldering multiple myeloma 40 years later: a story of unintended disease.
Expert Rev Hematol. 2021 Feb;14(2):149-153. doi: 10.1080/17474086.2021.1875815. Epub 2021 Jan 21.
6
Risk Stratification of Precursors to Multiple Myeloma in 2020.
R I Med J (2013). 2020 Apr 1;103(3):46-47.
7
Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.
Hematol Oncol Clin North Am. 2024 Apr;38(2):293-303. doi: 10.1016/j.hoc.2023.12.001. Epub 2023 Dec 28.
8
High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
Best Pract Res Clin Haematol. 2020 Mar;33(1):101152. doi: 10.1016/j.beha.2020.101152. Epub 2020 Jan 25.
9
Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
Br J Haematol. 2017 Dec;179(5):849-851. doi: 10.1111/bjh.14266. Epub 2016 Sep 8.
10
Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
Eur J Intern Med. 2018 Dec;58:57-63. doi: 10.1016/j.ejim.2018.05.029. Epub 2018 Jun 12.
引用本文的文献
1
[Progress in risk stratification and treatment of high-risk smoldering multiple myeloma].
Zhonghua Xue Ye Xue Za Zhi. 2024 Dec 14;45(12):1148-1152. doi: 10.3760/cma.j.cn121090-20240416-00144.
2
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database.
Blood Cancer J. 2024 Dec 5;14(1):215. doi: 10.1038/s41408-024-01170-z.
3
Smoldering multiple myeloma: Integrating biology and risk into management.
Semin Hematol. 2025 Feb;62(1):3-10. doi: 10.1053/j.seminhematol.2024.10.002. Epub 2024 Oct 18.
4
Evaluating early intervention in smoldering myeloma clinical trials: a systematic review.
Oncologist. 2025 Feb 6;30(2). doi: 10.1093/oncolo/oyae219.
5
Is It Possible to Predict Tumor Progression Through Genomic Characterization of Monoclonal Gammopathy and Smoldering Multiple Myeloma?
Mediterr J Hematol Infect Dis. 2024 May 1;16(1):e2024044. doi: 10.4084/MJHID.2024.044. eCollection 2024.
6
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone.
medRxiv. 2024 Apr 19:2024.04.19.24306082. doi: 10.1101/2024.04.19.24306082.
7
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma.
Clin Cancer Res. 2024 Oct 1;30(19):4482-4490. doi: 10.1158/1078-0432.CCR-24-0210.
8
Challenges in designing and running smouldering myeloma interventional clinical trials.
EJHaem. 2024 Mar 27;5(2):418-420. doi: 10.1002/jha2.880. eCollection 2024 Apr.
9
Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey.
EClinicalMedicine. 2023 Oct 24;65:102272. doi: 10.1016/j.eclinm.2023.102272. eCollection 2023 Nov.
10
Is aggressive treatment of smoldering myeloma the path to curing myeloma?
Blood Adv. 2023 Aug 8;7(15):3932-3935. doi: 10.1182/bloodadvances.2023009658.
Zotero 插件